IND (Investigational New Drug)

An application submitted to the FDA that allows a compound to be administered to humans in clinical trials. The IND application must include preclinical data demonstrating safety, manufacturing information, and a proposed clinical trial protocol. An IND is required before any clinical testing can begin in the United States. The IND status of a peptide is an important indicator of its position in the development pipeline.